Viking Therapeutics, Inc. - Common Stock — Financial Statistics (NASDAQ:VKTX) | MetaTrader

Open full chart

News

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?

HTX Lists AKAM, VKTX, H100, FOXA, INTU, CT Perpetual Contracts

Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

VKTX Advances Obesity Program With New Oral Maintenance Study

INSM Stock Slides on CFO Exit, Reiterates '26 Sales View

VKTX Down 16% in a Month: Time to Invest or Exit the Stock?

Viking Therapeutics Begins Exploratory Oral Maintenance Dosing Study Of VK2735, Its Dual Agonist Of Glucagon-Like Peptide 1 And Glucose-Dependent Insulinotropic Polypeptide Receptors

LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies

Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors